hyperprolactinemia/vomiting

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 42 rezilta yo

Primary Amenorrhea Associated with Hyperprolactinemia in Polyglandular Autoimmune Syndrome Type II: A Case Report.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Polyglandular autoimmune syndrome type II (PGA-II) is a rare immunoendocrinopathy syndrome characterized by the occurrence of autoimmune Addison disease along with diabetes mellitus type 1 and/or autoimmune thyroid disease. Here, we report the case of a 23-year-old female with PGA-II who was

A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Pergolide is a synthetic ergoline derivative with highly potent long-acting PRL-lowering activity, allowing therapy of hyperprolactinemia with a once daily administration of the drug. The results of two open-label, randomized controlled multicenter clinical trials are reported. Pergolide (taken once

Dopamine agonists for preventing future miscarriage in women with idiopathic hyperprolactinemia and recurrent miscarriage history.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Hyperprolactinemia is the presence of abnormally high circulating levels of prolactin. Idopathic hyperprolactinemia is the term used when no cause of prolactin hypersecretion can be identified and it is causally related to the development of miscarriage in pregnant women, especially women

[Terguride in hyperprolactinemia--experiences with 5 patients].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Hyperprolactinemia can successfully be treated by dopaminagonists such as bromocriptin or lisuride. About 10% of patients complain about side effects like orthostatic hypotension, nausea or vomiting, which may lead to discontinuation of treatment. We therefore conducted a study using terguride--a

Tumor-grade hyperprolactinemia induced by multiple medications in the setting of renal failure.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To describe a patient with galactorrhea and severe hyperprolactinemia in whom workup revealed a nontumoral mechanism. METHODS We present the medical history of a woman with long-standing diabetes in whom bilateral galactorrhea and hyperprolactinemia developed. In addition, the details of

Comparison of the clinical activity of mesulergine and pergolide in the treatment of hyperprolactinaemia.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The clinical activity of the new ergoline, mesulergine, was compared to pergolide in the treatment of hyperprolactinaemia. Mesulergine was given to 22 women and five men with hyperprolactinaemia. Serum prolactin was substantially lowered in 10 women; two subsequently conceived and completed normal

Dopamine agonists in the treatment of hyperprolactinemia. Comparison between bromocriptine and lisuride.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

27 patients (12 women and 15 men) with hyperprolactinemia were treated with the dopamine agonists lisuride (Dopergin) and bromocriptine on a cross-over basis for 3-6 months. By this treatment, plasma prolactin levels were reduced by 83 and 87%, and normalization was achieved in 13 patients in the

Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Cabergoline is a synthetic ergoline which shows high specificity and affinity for the dopamine D2 receptor. It is a potent and very long-acting inhibitor of prolactin secretion. Prolactin-lowering effects occur rapidly and, after a single dose, were evident at the end of follow up (21 days) in

Effect of hydergine in hyperprolactinemia.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The PRL-inhibiting and ovulation-inducing effects of hydergine were studied in 18 patients with hyperprolactinemic ovulatory disturbances. The women were divided into 2 groups of 9 each. Those in group A had basal serum PRL levels higher than 100 micrograms/L, and those in group B had basal serum

[The H2-antagonist therapy withdrawal syndrome: the possible role of hyperprolactinemia].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Patients previously treated with H2-receptor blocking agents (cimetidine or ranitidine) exhibited a complex neurobehavioral and gastroenteric syndrome, including anxiety, insomnia, anorexia, growing thin, irritability, tachycardia, diarrhoea, nausea, vomiting, abdominal pain, headache, vertigo.

A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Dopamine agonists are the treatment of choice for the majority of patients with hyperprolactinaemic disorders. Although characterised by a relatively high incidence of adverse effects, most commonly gastrointestinal, cardiovascular and neurological, these are usually mild and transient, and can be

[Symptomatic Rathke's cleft cyst: a clinicopathologic study of 9 cases].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Nine cases of symptomatic Rathke's cleft cyst are reported. Their most frequent signs and symptoms included headache, chiasmal syndrome and hypopituitarism, while one of the cases developed a sudden onset of headache and vomiting following diabetes insipidus. Endocrinological findings showed a

Pergolide mesylate: its effects on circulating anterior pituitary hormones in man.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Pergolide mesylate is a synthetic ergoline with dopamine agonist properties. The endocrine profile was studied in a double blind crossover design in six normal males. Circulating PRL, TSH, GH, LH, FSH, and cortisol were measured in the basal state and after TRH (500 micrograms iv) administration at

SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

SCH 23390 [R-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepine-7-ol) possesses pharmacologic effects similar to standard antipsychotics, including selective supression of conditioned avoidance responding in rats and squirrel monkeys, blockade of apomorphine-induced stereotypy in

[A case of prolactinoma with galactorrhea in man].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A 28-year-old man was admitted to the Kyushu University Hospital with an episode of severe headache. When driving a car, he suddenly developed severe headache and this was followed by nausea and vomiting. he had been quite well except for slightly decreased libido before this episode. On admission,

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye